GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Bought by Czech National Bank

Czech National Bank raised its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 6.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 99,060 shares of the company's stock after buying an additional 6,034 shares during the quarter. Czech National Bank's holdings in GE HealthCare Technologies were worth $7,745,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Mesirow Financial Investment Management Inc. increased its holdings in shares of GE HealthCare Technologies by 39.6% in the third quarter. Mesirow Financial Investment Management Inc. now owns 4,084 shares of the company's stock valued at $383,000 after purchasing an additional 1,159 shares during the period. LMR Partners LLP acquired a new position in GE HealthCare Technologies in the 3rd quarter valued at $7,387,000. Principal Financial Group Inc. boosted its holdings in shares of GE HealthCare Technologies by 1.9% in the third quarter. Principal Financial Group Inc. now owns 1,009,910 shares of the company's stock valued at $94,780,000 after acquiring an additional 19,010 shares in the last quarter. Everence Capital Management Inc. lifted its position in GE HealthCare Technologies by 118.2% in the fourth quarter. Everence Capital Management Inc. now owns 18,870 shares of the company's stock valued at $1,475,000 after purchasing an additional 10,220 shares during the period. Finally, B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in GE HealthCare Technologies in the 3rd quarter valued at approximately $1,396,000. 82.06% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Roland Rott sold 3,577 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total value of $309,338.96. Following the completion of the sale, the chief executive officer now owns 24,298 shares in the company, valued at approximately $2,101,291.04. This trade represents a 12.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.27% of the stock is owned by insiders.

GE HealthCare Technologies Trading Down 0.6 %

GEHC stock traded down $0.47 during midday trading on Wednesday, hitting $83.66. The stock had a trading volume of 4,148,593 shares, compared to its average volume of 3,399,888. GE HealthCare Technologies Inc. has a 12-month low of $71.31 and a 12-month high of $94.55. The firm has a market cap of $38.22 billion, a PE ratio of 22.98, a price-to-earnings-growth ratio of 2.90 and a beta of 1.11. The company's 50-day moving average price is $82.13 and its 200 day moving average price is $84.27. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.23 and a quick ratio of 0.98.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.14 EPS for the quarter, beating analysts' consensus estimates of $1.06 by $0.08. The company had revenue of $4.86 billion during the quarter, compared to the consensus estimate of $4.87 billion. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The company's quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.99 EPS. On average, equities research analysts predict that GE HealthCare Technologies Inc. will post 4.3 earnings per share for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Tuesday, January 14th will be given a dividend of $0.035 per share. This represents a $0.14 dividend on an annualized basis and a yield of 0.17%. This is a boost from GE HealthCare Technologies's previous quarterly dividend of $0.03. The ex-dividend date is Tuesday, January 14th. GE HealthCare Technologies's payout ratio is 3.85%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Stifel Nicolaus increased their target price on GE HealthCare Technologies from $100.00 to $102.00 and gave the stock a "buy" rating in a research note on Monday, September 30th. Jefferies Financial Group raised shares of GE HealthCare Technologies from a "hold" rating to a "buy" rating and increased their target price for the company from $95.00 to $103.00 in a report on Wednesday, January 8th. UBS Group cut GE HealthCare Technologies from a "neutral" rating to a "sell" rating and lowered their price target for the stock from $84.00 to $74.00 in a report on Thursday, September 26th. Wells Fargo & Company boosted their target price on GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an "overweight" rating in a research report on Thursday, October 31st. Finally, Evercore ISI upped their target price on GE HealthCare Technologies from $98.00 to $102.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $96.00.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.